Double blind, randomized, placebo-controlled, multi-center, phase II dose ranging study to assess the antifibrotic activity of farglitazar in chronic hepatitis C infection.

• Authors: MCHUTCHINSON John G; GOODMAN Zachary D; MAKLOUF Hala R; RODRIGUEZ-TORRES Maribel; SHIFFMAN Mitchell L; ROCKEY Don C; HUSA Petr; CHUANG Wan-Long, et al.
• Year of publication: 2008
• Type: Article in Periodical
• Magazine / Source: Hepatology
• MU Faculty or unit: Faculty of Medicine
• Field: Epidemiology, infectious diseases and clinical immunology